Talha Badar: PII Trial of CPX-351 and Venetoclax
Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X, about a recent article by Tapan M. Kadia et al, adding:
“American Journal of Hematology | Blood Research Journal | Wiley Online Library
PII trial of CPX-351 and Venetoclax, led by Dr. Tapan Kadia
CPX-351 dosed at daunorubicin 44 mg/m2 on days 1,3, and 5 and VEN 300 mg days 2–8) being chosen as the RP2D
- RR AML (58% prior Ven, 30% prior alloHCT)
- Composite CR 39%.
- 11 (73%) bridged to alloHCT.
- 30 and 60 day TRM, 9% and 21%.
- 2 yrs OS 49%.
Title: A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Authors: Tapan M. Kadia, Wei-Ying Jen, Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Elias Jabbour, Wei Qiao, Nicholas J. Short, Koichi Takahashi, Ghayas C. Issa, Courtney D. DiNardo, Guillermo Montalban-Bravo, Naveen Pemmaraju, Andrew Tran, Vanthana Bharathi, Sanam Loghavi, Amin M. Alousi, Uday Popat, Naval G. Daver, Farhad Ravandi, Hagop M. Kantarjian
Read the Full Article on American Journal of Hematology
More posts featuring Talha Badar.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023